Related Experiment Video
Updated: May 4, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 19, 2013
Should an institution that has commercial rights in a new drug or device be allowed to evaluate the technology?
1Duke University School of Medicine, Durham, North Carolina, USA. ross.mckinney@duke.edu
Background To The Debate:
In the United States, the passage of the Bayh-Dole Act in 1980 encouraged universities to license inventions for commercial development. Although this financial incentive can stimulate academic researchers to discover new drugs and devices, there is concern that the possibility of monetary reward could distort investigators' objectivity.
Related Concept Videos
Clinical Trials: Overview
Drug Regulation
Preclinical Development: Overview
Drug Control Governance: Regulatory Bodies and Their Impact
Drug Products: Biologics, Biosimilars and Interchangeables
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

